District court rules against Lilly in Strattera patent suit

INDIANAPOLIS The U.S. District Court for the District of New Jersey has ruled against drug maker Eli Lilly in its patent infringement case against generic drug maker Actavis regarding a drug used to treat attention deficit hyperactivity disorder, Lilly said.

The court ruled that a method-of-use patent covering the drug, Strattera (atomoxetine), was invalid. The patent was set to expire in May 2017.

Lilly said it would appeal, but expects a generic version of Strattera to enter the market in the near term as a result of the decision.

Login or Register to post a comment.